Siemens, Medtronic jump through antitrust regulatory hoops
This article was originally published in Clinica
US antitrust authorities has given the go-ahead to Siemens' proposed $7bn acquisition of Dade Behring, the German multinational's third and largest IVD transaction. Siemens began a tender offer for all issued and outstanding Dade stock, at $77 per share, on August 8 and has extended this offer until midnight September 26. The acquisition still requires EU antitrust approval - Siemens said it is in discussion with the European Commission and believes it can close the transaction during calendar 2007.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.